Although different routes and delivery systems have been used to deliver interferon-g (IFN-g) for the treatment of a variety of viral and neoplastic diseases, little has been reported regarding the most efยฎcient and least toxic routes and drug delivery modes required to achieve these goals. To have
Interleukin-2: Evaluation of routes of administration and current delivery systems in cancer therapy
โ Scribed by Mohamed A. Shaker; Husam M. Younes
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 354 KB
- Volume
- 98
- Category
- Article
- ISSN
- 0022-3549
No coin nor oath required. For personal study only.
โฆ Synopsis
Despite the fact that different administration routes and delivery systems have been used for interleukin-2 (IL-2) delivery, little has been reported regarding the most efficient strategies used to deliver IL-2 in a nontoxic, efficient, stable and safe manner. Systemic IL-2 administration has always been associated with rapid clearance and severe toxicity as a result of its narrow therapeutic index. Loco-regional IL-2 delivery, however, is used to localize IL-2 actions and activities into the vicinity of tumors and can result in an improved therapeutic outcome with much less side effects or toxicity. The purpose of this review is to report on the different properties and aspects of IL-2, including its mechanism of action, physicochemical properties, and structure which have an impact on the activity, stability and formulation of IL-2 dosage forms and delivery systems. In addition, advantages and limitations of the currently available techniques and strategies to deliver IL-2 will also be covered.
๐ SIMILAR VOLUMES
lnterleukin 2 (IL-2) administration is known to induce marked eosinophilia. To evaluate the potential role of eosinophils as anti-tumor effectors and t o understand the direct or indirect effects of IL-2 on eosinophils, the physical and functional characteristics of eosinophils obtained during IL-2
## BACKGROUND. Administration of recombinant high dose interleukin-2 (IL-2) can mediate tumor regression in patients with metastatic melanoma and renal carcinoma. Significant trends in the safety of high dose IL-2 administration at a single institution over a 12-year study period were reviewed. #
The authors performed a Phase I study to assess the toxicity and hematologic effect of recombinant human interleukin-2 (rIL-2) in seven children with advanced malignancies. The rIL-2 was given as a bolus injection of 1 or 3 X lo6 U/m2/dose three times a week (Monday, Wednesday, and Friday) for 3 wee